Oppenheimer analyst Jay Olson assigned a Hold rating to Intercept Pharma (ICPT) yesterday and set a price target of $20.00. The company’s shares closed last Friday at $17.15, close to its 52-week low of $16.81.
According to TipRanks.com, Olson is a 3-star analyst with an average return of 3.4% and a 47.7% success rate. Olson covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Madrigal Pharmaceuticals, and Crispr Therapeutics AG.
Currently, the analyst consensus on Intercept Pharma is a Moderate Buy with an average price target of $34.80, which is a 103.0% upside from current levels. In a report issued on May 6, Stifel Nicolaus also reiterated a Hold rating on the stock with a $16.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $95.98 and a one-year low of $16.81. Currently, Intercept Pharma has an average volume of 1.13M.
Based on the recent corporate insider activity of 71 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ICPT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
